Brief: Cullinan Oncology Announces U.S. FDA Clearance Of Investigational New Drug Application For Cln-978, A Novel T-Cell Engager For The Treatment Of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Cullinan Therapeutics

24/01/2023 13:17

Jan 24 (Reuters) - Cullinan Oncology Inc  CGEM.O :
    * CULLINAN ONCOLOGY ANNOUNCES U.S. FDA CLEARANCE OF
INVESTIGATIONAL NEW DRUG APPLICATION FOR CLN-978, A NOVEL T-CELL
ENGAGER FOR THE TREATMENT OF RELAPSED/REFRACTORY B-CELL
NON-HODGKIN LYMPHOMA
    * CULLINAN ONCOLOGY INC - IND SUBMISSION REMAINS ON TRACK
FOR
CLN-617 (IL-2, IL-12 FUSION PROTEIN) IN 1H 2023

Source text for Eikon:  ID:nGNX7XHtWQ 
Further company coverage:  CGEM.O 
 ((Reuters.Briefs@thomsonreuters.com;;))